Inflammation and Immunology Translational Development, Celgene Corporation , Summit, NJ , USA.
Front Neurol. 2013 Oct 30;4:169. doi: 10.3389/fneur.2013.00169. eCollection 2013.
Teriflunomide is an oral disease-modifying therapy recently approved in several locations for relapsing-remitting multiple sclerosis. To gain insight into the effects of teriflunomide, immunocyte population changes were measured during progression of experimental autoimmune encephalomyelitis in Dark Agouti rats. Treatment with teriflunomide attenuated levels of spinal cord-infiltrating T cells, natural killer cells, macrophages, and neutrophils. Teriflunomide also mitigated the disease-induced changes in immune cell populations in the blood and spleen suggesting an inhibitory effect on pathogenic immune responses.
特立氟胺是一种新型口服免疫抑制剂，已在多个国家和地区被批准用于治疗多发性硬化症的复发缓解型。为了研究特立氟胺的作用机制，我们在实验性自身免疫性脑脊髓炎的进展过程中，观察了特立氟胺对免疫细胞群体变化的影响。结果显示，特立氟胺可减轻实验性自身免疫性脑脊髓炎大鼠脊髓浸润的 T 细胞、自然杀伤细胞、巨噬细胞和中性粒细胞的水平。特立氟胺还减轻了疾病引起的血液和脾脏中免疫细胞群的变化，提示其对致病性免疫应答具有抑制作用。
